Use of Ependymoma Cell Lines to Test for New Therapeutic Vulnerabilities

Ependymoma is a disease with nine distinct forms where two of the most common and aggressive forms occur primarily in children. Research into the main drivers of each form has been successful, but there are still very few therapeutic options available to patients. Recent studies have identified vulnerabilities in the ependymoma genome that may pave the way for new therapies. Newly established ependymoma cell cultures from the CBTN will be utilized to validate these discoveries.